Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $31.60 Consensus Price Target from Analysts

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have been given an average recommendation of “Hold” by the six brokerages that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $31.60.

Several brokerages have issued reports on AMPH. Bank of America boosted their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 26th. Weiss Ratings reissued a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, October 8th. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, August 8th. Finally, Needham & Company LLC raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a research note on Tuesday, August 12th.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. TD Asset Management Inc raised its position in shares of Amphastar Pharmaceuticals by 20.2% during the first quarter. TD Asset Management Inc now owns 2,212,142 shares of the company’s stock worth $64,130,000 after purchasing an additional 371,856 shares during the period. Fuller & Thaler Asset Management Inc. raised its position in shares of Amphastar Pharmaceuticals by 11.5% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company’s stock worth $36,632,000 after purchasing an additional 130,672 shares during the period. Epoch Investment Partners Inc. raised its position in shares of Amphastar Pharmaceuticals by 14.5% during the first quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company’s stock worth $36,565,000 after purchasing an additional 160,034 shares during the period. Boston Trust Walden Corp raised its position in shares of Amphastar Pharmaceuticals by 24.2% during the first quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company’s stock worth $35,241,000 after purchasing an additional 236,704 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Amphastar Pharmaceuticals by 1.9% during the second quarter. Geode Capital Management LLC now owns 973,237 shares of the company’s stock worth $22,348,000 after purchasing an additional 18,161 shares during the period. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH opened at $23.78 on Wednesday. Amphastar Pharmaceuticals has a 52-week low of $20.39 and a 52-week high of $53.96. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.21 and a current ratio of 3.29. The business’s 50 day moving average price is $27.86 and its two-hundred day moving average price is $25.27. The firm has a market cap of $1.11 billion, a PE ratio of 8.91 and a beta of 0.75.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.